S G Gauthier

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. doi request reprint Current and future management of Alzheimer's disease
    Serge Gauthier
    McGill Center for Studies in Aging, Douglas Institute for Mental Health, Montreal, Quebec, Canada
    Alzheimers Dement 4:S48-50. 2008
  2. doi request reprint Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE)
    Serge Gauthier
    McGill Centre for Studies of Aging, Montreal, Quebec, Canada
    Curr Med Res Opin 26:1149-60. 2010
  3. doi request reprint Diagnosis and management of Alzheimer's disease: past, present and future ethical issues
    S Gauthier
    McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal, Quebec, Canada Electronic address
    Prog Neurobiol 110:102-13. 2013
  4. doi request reprint Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study
    Serge Gauthier
    McGill Centre for Studies of Aging, Douglas Hospital, Montreal, Quebec, Canada
    Curr Med Res Opin 29:989-1000. 2013
  5. doi request reprint Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease
    Serge Gauthier
    McGill Centre for Studies in Aging, Alzheimer s Disease Research Unit, Montreal, Quebec, Canada
    Alzheimers Dement 9:326-31. 2013
  6. doi request reprint A 10-year perspective on donepezil
    Laksanun Cheewakriengkrai
    McGill Center for Studies in Aging, Montreal, Canada
    Expert Opin Pharmacother 14:331-8. 2013
  7. pmc Prevention strategies for Alzheimer's disease
    Serge Gauthier
    McGill Center for Studies in Aging, McGill University, Montreal, Canada
    Transl Neurodegener 1:13. 2012
  8. pmc Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice
    Vjera A Holthoff
    Old Age Psychiatry and Cognitive Neuropsychiatry, University Hospital Carl Gustav Carus, University of Technology, Fetscherstraße 74, Dresden 01307, Germany
    Alzheimers Res Ther 3:27. 2011
  9. pmc Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease
    Roy Jones
    Research Institute for the Care of Older People, Royal United Hospital, Combe Park, Bath BA1 3NG, UK
    Trials 12:233. 2011
  10. pmc Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?
    Philippe Robert
    Memory Center, CHU University of Nice Sophia Antipolis, hopital de Cimiez, 4 av Victoria, 06000 Nice, France
    Alzheimers Res Ther 2:24. 2010

Collaborators

Detail Information

Publications74

  1. doi request reprint Current and future management of Alzheimer's disease
    Serge Gauthier
    McGill Center for Studies in Aging, Douglas Institute for Mental Health, Montreal, Quebec, Canada
    Alzheimers Dement 4:S48-50. 2008
    ..There are multiple research opportunities for better understanding and treatment of this condition. Ongoing cohort studies developed under Leon Thal's leadership will facilitate this process...
  2. doi request reprint Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE)
    Serge Gauthier
    McGill Centre for Studies of Aging, Montreal, Quebec, Canada
    Curr Med Res Opin 26:1149-60. 2010
    ..To evaluate, in a real-world clinical setting, the efficacy of rivastigmine in the management of six symptoms commonly associated with Alzheimer's disease (AD)...
  3. doi request reprint Diagnosis and management of Alzheimer's disease: past, present and future ethical issues
    S Gauthier
    McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal, Quebec, Canada Electronic address
    Prog Neurobiol 110:102-13. 2013
    ..We here summarize and discuss the different ethical issues associated with AD from a historical perspective, with emphasis on diagnostic and treatments issues. ..
  4. doi request reprint Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study
    Serge Gauthier
    McGill Centre for Studies of Aging, Douglas Hospital, Montreal, Quebec, Canada
    Curr Med Res Opin 29:989-1000. 2013
    ..To assess the real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease (AD) in Canada...
  5. doi request reprint Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease
    Serge Gauthier
    McGill Centre for Studies in Aging, Alzheimer s Disease Research Unit, Montreal, Quebec, Canada
    Alzheimers Dement 9:326-31. 2013
    ..Clinical studies and post hoc analyses have investigated the use of combination therapy for the treatment of Alzheimer's disease (AD). We review the evidence for the short- and long-term efficacy of combination therapy in AD...
  6. doi request reprint A 10-year perspective on donepezil
    Laksanun Cheewakriengkrai
    McGill Center for Studies in Aging, Montreal, Canada
    Expert Opin Pharmacother 14:331-8. 2013
    ..Its efficacy has been approved for use in mild-to-moderate AD stage for improvement of symptoms for 10 years, and now it is also approved for use in severe stage...
  7. pmc Prevention strategies for Alzheimer's disease
    Serge Gauthier
    McGill Center for Studies in Aging, McGill University, Montreal, Canada
    Transl Neurodegener 1:13. 2012
    ..This will be done first in carriers of dominantly inherited early onset AD. As this research takes place networks of memory clinics must prepare to transfer new knowledge to persons interested in a preventive approach to AD...
  8. pmc Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice
    Vjera A Holthoff
    Old Age Psychiatry and Cognitive Neuropsychiatry, University Hospital Carl Gustav Carus, University of Technology, Fetscherstraße 74, Dresden 01307, Germany
    Alzheimers Res Ther 3:27. 2011
    ..The validity and reliability of ROSA as well as sensitivity to changes due to intervention were examined in an open-label, single-arm, multicenter clinical study in patients with Alzheimer's disease (AD)...
  9. pmc Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease
    Roy Jones
    Research Institute for the Care of Older People, Royal United Hospital, Combe Park, Bath BA1 3NG, UK
    Trials 12:233. 2011
    ..We present here a successful example of this type of collaboration in the field of dementia...
  10. pmc Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?
    Philippe Robert
    Memory Center, CHU University of Nice Sophia Antipolis, hopital de Cimiez, 4 av Victoria, 06000 Nice, France
    Alzheimers Res Ther 2:24. 2010
    ....
  11. ncbi request reprint Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies
    S Gauthier
    MCSA Alzheimer s Disease Research Unit, McGill Centre for Studies in Aging, Quebec, Canada
    Int J Geriatr Psychiatry 20:459-64. 2005
    ..We have analysed the databases of two randomised studies with regard to the effects of memantine treatment on behavioural symptoms, measured using the 12-item version of the Neuropsychiatric Inventory (NPI)...
  12. pmc EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease
    S Gauthier
    Alzheimer s Disease Research Unit, McGill Centre for Studies of Aging, Montreal, QC, Canada
    Int J Clin Pract 61:886-95. 2007
    ..These real-life findings further demonstrate the proven efficacy of rivastigmine in patients with mild-to-moderate AD...
  13. ncbi request reprint Mild cognitive impairment is not a clinical entity and should not be treated
    Serge Gauthier
    Department of Neurology and Neurosurgery, McGill University and Alzheimer Disease Research Unit, McGill Centre for Studies in Aging, Montreal, Quebec, Canada
    Arch Neurol 62:1164-6; discussion 1167. 2005
  14. ncbi request reprint Does vascular MCI progress at a different rate than does amnestic MCI?
    Serge Gauthier
    McGill Centre for Studies in Aging, McGill University, Montreal, Canada
    Int Psychogeriatr 15:257-9. 2003
    ..The issues to be resolved prior to the use of a survival design for conversion from vascular MCI to dementia will be discussed...
  15. ncbi request reprint Mild cognitive impairment
    Serge Gauthier
    McGill Center for Studies in Aging, Douglas Hospital, Montreal, Quebec, Canada
    Lancet 367:1262-70. 2006
    ..Other definitions and subtypes of mild cognitive impairment need to be studied as potential prodromes of Alzheimer's disease and other types of dementia...
  16. ncbi request reprint Realizing early treatment benefits in dementia
    S G Gauthier
    Alzheimer Disease and Related Disorders Unit, McGill Centre for Studies in Aging, Douglas Hospital, Verdun PQ, Québec H4H 1RS, Canada
    Eur J Neurol 12:1-2. 2005
  17. ncbi request reprint Alzheimer's disease: the benefits of early treatment
    S G Gauthier
    Alzheimer Disease and Related Disorders Unit, McGill Centre for Studies in Aging, Douglas Hospital, Verdun PQ, Québec H4H 1RS, Canada
    Eur J Neurol 12:11-6. 2005
    ..Results of early studies of donepezil in MCI are promising and suggest directions for further research...
  18. ncbi request reprint A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study
    Serge Gauthier
    McGill Centre for Studies in Aging, Douglas Hospital, Montreal, Quebec, Canada
    Curr Med Res Opin 22:2251-65. 2006
    ....
  19. doi request reprint Pharmacotherapy of Parkinson disease dementia and Lewy body dementia
    Serge Gauthier
    McGill Center for Studies in Aging, Montreal, Quebec, Canada
    Front Neurol Neurosci 24:135-9. 2009
    ..Primary care practitioners play an essential role in the diagnosis and management of patients with these conditions...
  20. doi request reprint Can we do better in developing new drugs for Alzheimer's disease?
    Serge Gauthier
    Department of Psychiatry, Neurology and Neurosurgery, McGill Center for Studies in Aging, McGill University, Montreal, Quebec, Canada
    Alzheimers Dement 5:489-91. 2009
    ....
  21. doi request reprint Management of behavioral problems in Alzheimer's disease
    Serge Gauthier
    Alzheimer s Disease and Related Disorders Unit, McGill Center for Studies in Aging, Douglas Mental Health University Institute, Montreal, Canada
    Int Psychogeriatr 22:346-72. 2010
    ..Pharmacological treatment options, such as antipsychotics, antidepressants, anticonvulsants, cholinesterase inhibitors and memantine, need careful consideration of the benefits and limitations of each drug class...
  22. ncbi request reprint Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease
    S Gauthier
    Curr Med Res Opin 18:347-54. 2002
    ..To investigate the efficacy and safety of donepezil in a subgroup of patients with Alzheimer's disease (AD) of moderate severity from a previous trial...
  23. ncbi request reprint Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease
    Serge Gauthier
    Alzheimer s Disease Research Unit, McGill Centre for Studies in Aging, Verdun, Quebec, Canada
    Int Psychogeriatr 14:389-404. 2002
    ..This subanalysis of a large, double-blind, placebo-controlled trial examined the prevalence of behavioral symptoms in moderate to severe Alzheimer's disease (AD), and the effect of treatment with donepezil...
  24. ncbi request reprint Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis
    S Gauthier
    MCSA Alzheimer s Disease Research Unit, McGill Centre for Studies in Aging, Quebec, Canada
    Int J Geriatr Psychiatry 23:537-45. 2008
    ..Behavioural disturbances are a common and distressing aspect of Alzheimer's disease (AD). This pooled analysis evaluated the specific benefits of memantine on behavioural disturbances in patients with moderate to severe AD...
  25. pmc Advances in the pharmacotherapy of Alzheimer's disease
    Serge Gauthier
    Alzheimer s Disease Research Unit at the McGill Centre for Studies in Aging, McGill University, Montreal, Que
    CMAJ 166:616-23. 2002
  26. ncbi request reprint Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors
    Serge Gauthier
    McGill Centre for Studies in Aging, Verdun, Quebec, Canada
    Curr Med Res Opin 19:707-14. 2003
    ..The panel also aimed to reach consensus on 'whom to switch', 'when to switch' and 'how to switch'. The key findings from that meeting are reported in this review...
  27. doi request reprint Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease
    Serge Gauthier
    McGill Center for Studies in Aging, Douglas Mental Health University Institute, Douglas Hospital, Verdun, QC, Canada
    Int Psychogeriatr 22:973-83. 2010
    ....
  28. ncbi request reprint [Treatment of Alzheimer's disease: general methodological aspects]
    S Gauthier
    Unité de recherche sur la maladie d Alzheimer, centre McGill d études sur le vieillissement, Quebec, Canada H4H 1R3
    Rev Neurol (Paris) 160:261-4. 2004
    ..A preventive approach based on individual risk assessment may be possible, which will increase the number of consultations for neurologists in the near future...
  29. ncbi request reprint Working memory and control of attention in persons with Alzheimer's disease and mild cognitive impairment
    Sylvie Belleville
    Research CenterInstitut Universitaire de Geriatrie de Montreal, Montreal, PQ, Canada
    Neuropsychology 21:458-69. 2007
    ..These data suggest that control of attention tasks can track AD at a preclinical stage and that impairment increases gradually during the preclinical phase of AD...
  30. ncbi request reprint Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies
    Richard Camicioli
    Glenrose Rehabilitation Hospital, Edmonton, AB, Canada
    Can J Neurol Sci 34:S109-17. 2007
    ..At present PDD and DLB are distinct entities by definition. Future studies, including clinical trials and biomarker studies, will help to further define the clinical and therapeutic implications of this distinction...
  31. ncbi request reprint Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria
    Bruno Dubois
    INSERM U610, Hopital de la Salpetriere, Paris, France
    Lancet Neurol 6:734-46. 2007
    ..Validation studies in existing and prospective cohorts are needed to advance these criteria and optimise their sensitivity, specificity, and accuracy...
  32. ncbi request reprint Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease
    Hao Li
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Arch Neurol 65:45-53. 2008
    ..To identify single-nucleotide polymorphisms (SNPs) associated with risk and age at onset of Alzheimer disease (AD) in a genomewide association study of 469 438 SNPs...
  33. ncbi request reprint Clinical diagnostic criteria for dementia associated with Parkinson's disease
    Murat Emre
    Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
    Mov Disord 22:1689-707; quiz 1837. 2007
    ..Based on the characteristic features associated with this condition, clinical diagnostic criteria for probable and possible PD-D are proposed...
  34. ncbi request reprint Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease
    Barry Reisberg
    Int Psychogeriatr 20:1-16. 2008
  35. ncbi request reprint Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial
    Connie Marras
    Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Mov Disord 23:653-9; quiz 776. 2008
    ..Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL...
  36. ncbi request reprint Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force
    Bruno Dubois
    INSERM UPMC UMRS 610, Federation of Neurology, AP HP, Salpêtrière Hospital Université Paris6, Paris, France
    Mov Disord 22:2314-24. 2007
    ..We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies...
  37. doi request reprint Cognitive complaint in mild cognitive impairment and Alzheimer's disease
    Francis Clément
    Centre de recherche de l Institut universitaire de geriatrie de Montreal, Montreal, Canada
    J Int Neuropsychol Soc 14:222-32. 2008
    ....
  38. doi request reprint The association between depressive and cognitive symptoms in amnestic mild cognitive impairment
    Carol Hudon
    Ecole de Psychologie, Universite Laval, Quebec, Canada
    Int Psychogeriatr 20:710-23. 2008
    ..Depressive symptoms are frequently observed in older adults with mild cognitive impairment (MCI). However, little is known regarding the cognitive characteristics of this important subgroup...
  39. doi request reprint Transition from cognitively impaired not demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohort
    Ging Yuek R Hsiung
    Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
    Dement Geriatr Cogn Disord 25:483-90. 2008
    ..We evaluated whether impairments on the Disability Assessment for Dementia (DAD) and Functional Rating Scale (FRS) can predict progression to AD...
  40. ncbi request reprint Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer disease
    Jan Marcusson
    Department of Geriatric Medicine, Linkoping University Hospital, Linkoping, Sweden
    Alzheimer Dis Assoc Disord 17:S86-91. 2003
    ..Prescribing approved therapies such as galantamine for older patients with AD is recommended...
  41. doi request reprint Task switching capacities in persons with Alzheimer's disease and mild cognitive impairment
    Sylvie Belleville
    Research Center, Institut Universitaire de Geriatrie de Montreal, Canada
    Neuropsychologia 46:2225-33. 2008
    ..The pattern across condition is coherent with a continuum between those two clinical groups...
  42. ncbi request reprint Outcomes for assessment of symptomatic and stabilization/disease modifying drugs
    Serge Gauthier
    Alzheimer Disease Research Unit, McGill Centre for Studies in Aging, Verdun, Quebec, Canada
    Can J Neurol Sci 34:S23-6. 2007
    ..Delaying progression to disease milestones may offer additional validity to these studies. It is unclear if biological and neuroimaging markers will add to the clinical evidence...
  43. pmc Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI
    Clifford R Jack
    Department of Radiology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Neurobiol Aging 29:1285-95. 2008
    ..000). Results of this study support the feasibility of using MRI as an outcome measure of disease progression in multi center therapeutic trials for MCI...
  44. ncbi request reprint Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial
    Timo Erkinjuntti
    Department of Clinical Neurosciences, Helsinki University Central Hospital, Helsinki, Finland
    Lancet 359:1283-90. 2002
    ..We investigated the effects of galantamine in patients with a diagnosis of probable vascular dementia or Alzheimer's disease combined with cerebrovascular disease...
  45. ncbi request reprint Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial
    Howard Feldman
    Division of Neurology, University of British Columbia, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, BC, Canada
    Int J Geriatr Psychiatry 20:559-69. 2005
    ..Additional analyses examined whether donepezil's treatment effects were consistent across the full range of baseline AD severity studied (sMMSE score 5-17)...
  46. pmc Drugs for Alzheimer's disease and related dementias
    Serge Gauthier
    BMJ 330:857-8. 2005
  47. ncbi request reprint Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors
    Timo Erkinjuntti
    Helsinki University Central Hospital, Helsinki, Finland
    J Neurol Sci 226:63-6. 2004
    ..Controlled clinical trials with donepezil, galantamine and rivastigmine in VaD, as well as in patients with AD plus CVD, have demonstrated improvements in cognition, behavior and activities of daily living...
  48. pmc The benefits of apolipoprotein E epsilon4 screening to research
    Serge Gauthier
    Alzheimer s Disease Research Unit, McGill Centre for Studies in Aging, Verdun, Que
    CMAJ 171:881. 2004
  49. ncbi request reprint Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors
    Timo Erkinjuntti
    Helsinki University Central Hospital, Finland
    Neurol Res 26:603-5. 2004
    ..Controlled clinical trials with donepezil, galantamine, and rivastigmine in VaD, as well as in patients with AD plus CVD, have demonstrated improvement in cognition, behavior and activities of daily living...
  50. ncbi request reprint Emerging therapies for vascular dementia and vascular cognitive impairment
    Timo Erkinjuntti
    Helsinki University Central Hospital, Helsinki, Finland
    Stroke 35:1010-7. 2004
    ..Cerebrovascular disease (CVD) and ischemic brain injury secondary to cardiovascular disease are common causes of dementia and cognitive decline in the elderly. CVD also contributes to cognitive loss in Alzheimer disease (AD)...
  51. ncbi request reprint Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials
    Michael Grundman
    Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
    Arch Neurol 61:59-66. 2004
    ..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD...
  52. ncbi request reprint Dementia with Lewy bodies
    Ian McKeith
    Institute for Ageing and Health, University of Newcastle, Newcastle upon Tyne, UK
    Lancet Neurol 3:19-28. 2004
    ..Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life...
  53. ncbi request reprint The Consortium to Investigate Vascular Impairment of Cognition: methods and first findings
    Kenneth Rockwood
    Dalhousie University, Halifax, NS, Canada
    Can J Neurol Sci 30:237-43. 2003
    ..We report its organization and the impact of diagnostic criteria on the study of VCI...
  54. ncbi request reprint Alzheimer's disease: the pharmacological pathway
    Herve Allain
    Laboratoire de Pharmacologie Experimentale et Clinique, Faculte de Medecine, Universite de Rennes I, CS 34317, 35043 Rennes Cedex, France
    Fundam Clin Pharmacol 17:419-28. 2003
    ..The rapidity at which these compounds will be at our disposal is highly dependent on the policy of the pharmaceutical companies...
  55. ncbi request reprint Vascular cognitive impairment
    John T O'Brien
    Institute for Aging and Health, Newcastle General Hospital, Newcastle upon Tyne, UK
    Lancet Neurol 2:89-98. 2003
    ..Clinical trials in vascular cognitive impairment are in their infancy but support the value of therapeutic interventions for symptomatic treatment...
  56. ncbi request reprint Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden
    Howard Feldman
    Division of Neurology, UBC Hospital, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, British Columbia, Canada
    J Am Geriatr Soc 51:737-44. 2003
    ....
  57. ncbi request reprint Clinical and radiographic subtypes of vascular cognitive impairment in a clinic-based cohort study
    Kenneth Rockwood
    Dalhousie University, Canada
    J Neurol Sci 240:7-14. 2006
    ..There is a need for empirical studies to define criteria for vascular cognitive impairment (VCI) subtypes. In this paper, we report the predictive validity of a subtype classification scheme based on clinical and radiographic features...
  58. ncbi request reprint Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies
    Nadeem H Bhanji
    Clinical Pharmacology Unit, Allan Memorial Institute, McGill University Health Centre, 1025 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1
    J Neuropsychiatry Clin Neurosci 17:552-5. 2005
    ..In this study, complications (insomnia, dyskinesias, agitation, and delirium) occurred in three patients switched from donepezil to galantamine. The authors describe evidence-based recommendations for ChEI switchover in DLB...
  59. pmc Use of memantine to treat Alzheimer's disease
    Serge Gauthier
    CMAJ 175:501-2. 2006
  60. ncbi request reprint Memory for gist and detail information in Alzheimer's disease and mild cognitive impairment
    Carol Hudon
    Centre de recherche de l Institut universitaire de geriatrie de Montreal, PQ, Canada
    Neuropsychology 20:566-77. 2006
    ..The discrepancy in MCI participants might be explained by differences in the degree of sensitivity of the experimental procedures and/or by the differences in the cognitive processes these procedures assessed...
  61. pmc Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy
    Florian Ferreri
    Alzheimer s Disease Research Unit, McGill Centre for Studies in Aging, Douglas Hospital, Verdun, Montreal, Que
    J Psychiatry Neurosci 31:369-76. 2006
    ..We aimed to review the literature and evaluate the overall effectiveness of ChEI adjunctive therapy for the management of cognitive dysfunctions in schizophrenia...
  62. ncbi request reprint Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary
    Howard H Feldman
    Division of Neurology, University of British Columbia, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, BC, Canada
    Can J Neurol Sci 33:6-26. 2006
    ..They are intended to provide a common point of reference and guidance in Canada for therapeutic development of the dementias...
  63. ncbi request reprint Disease progression in vascular cognitive impairment: cognitive, functional and behavioural outcomes in the Consortium to Investigate Vascular Impairment of Cognition (CIVIC) cohort study
    Kenneth Rockwood
    Dalhousie University, Canada
    J Neurol Sci 252:106-12. 2007
    ..We compared cognitive, functional, and behavioural outcomes in patients with VCI to patients with no cognitive impairment (NCI), and Alzheimer's disease (AD)...
  64. ncbi request reprint Improvement of episodic memory in persons with mild cognitive impairment and healthy older adults: evidence from a cognitive intervention program
    Sylvie Belleville
    Institut Universitaire de Geriatrie de Montreal, Montreal, Canada
    Dement Geriatr Cogn Disord 22:486-99. 2006
    ..These results suggest that persons with MCI can improve their performance on episodic memory when provided with cognitive training...
  65. pmc Recognition and management of neuropsychiatric complications in Parkinson's disease
    Florian Ferreri
    Alzheimer s Disease Research Unit, McGill Centre for Studies in Aging, Douglas Hospital, Verdun, Quebec, Canada
    CMAJ 175:1545-52. 2006
    ..In this article, we review the key clinical features of neuropsychiatric complications in Parkinson's disease as well as what is known about their epidemiologic characteristics, risk factors, pathophysiologic features and management...
  66. pmc Expression of melanotransferrin isoforms in human serum: relevance to Alzheimer's disease
    Richard R Desrosiers
    Laboratoire de Medecine Moleculaire, Hopital Sainte Justine, Universite du Quebec a Montreal, C P 8888, Succursale Centre Ville, Montreal, Quebec, Canada H3C 3P8
    Biochem J 374:463-71. 2003
    ..These data also indicate that human serum melanotransferrin levels are unchanged in subjects with Alzheimer's disease...
  67. ncbi request reprint REM sleep behavior disorder and REM sleep without atonia in probable Alzheimer disease
    Jean Francois Gagnon
    Centre d Etude du Sommeil et des Rythmes Biologiques, Hopital du Sacre Coeur de Montreal, Qudbec, Canada
    Sleep 29:1321-5. 2006
    ..To determine the frequency of rapid eye movement (REM) sleep behavior disorder (RBD) and REM sleep without atonia among patients with Alzheimer disease and control subjects...
  68. ncbi request reprint Alzhemed: a potential treatment for Alzheimer's disease
    Paul S Aisen
    Department of Neurology, Georgetown University, Washington, DC 20057, USA
    Curr Alzheimer Res 4:473-8. 2007
    ..These findings will be discussed in the context of two large-scale randomized, double-blind, placebo-controlled Phase III clinical trials that are currently being conducted to test the long-term safety and efficacy of Alzhemed...
  69. ncbi request reprint Pharmacotherapy of Alzheimer disease
    Dennis Seow
    Alzheimer Disease Research Unit, McGill Centre for Studies in Aging, Montreal, Quebec
    Can J Psychiatry 52:620-9. 2007
    ..To systematically review published clinical trials of the pharmacotherapy of Alzheimer disease (AD)...
  70. ncbi request reprint Cholinesterase inhibitors in late-stage Alzheimer's disease
    Serge Gauthier
    Lancet Neurol 5:468-9. 2006
  71. ncbi request reprint Reliability and validity of the Safety Assessment Scale for people with dementia living at home
    Courval Louise de Poulin
    Department of Family Medicine, McGill University, Cote des Neiges, Montreal
    Can J Occup Ther 73:67-75. 2006
    ..With the recent funding changes in health care services, more seniors with dementia are cared for in their homes and the nature of their condition puts them at higher risk for accidents and injuries...
  72. doi request reprint Revised research diagnostic criteria for Alzheimer's disease
    Serge Gauthier
    Lancet Neurol 7:668-70. 2008
  73. pmc Managing discontinuation syndrome in patients with dementia
    Serge Gauthier
    McGill Center for Studies in Aging, Montreal, Que
    J Psychiatry Neurosci 31:72. 2006
  74. pmc A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium
    Zaven S Khachaturian
    Alzheimers Dement 4:156-63. 2008